3 days ago
Truist Financial Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)
In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Kymera Therapeutics (KYMR – Research Report), with a price target of $53.00.
Confident Investing Starts Here:
According to TipRanks, Devarakonda is an analyst with an average return of -5.9% and a 32.60% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as Cytokinetics, Regeneron, and Scholar Rock Holding.
In addition to Truist Financial, Kymera Therapeutics also received a Buy from Citi's Geoff Meacham in a report issued today. However, yesterday, Morgan Stanley maintained a Hold rating on Kymera Therapeutics (NASDAQ: KYMR).
Based on Kymera Therapeutics' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $22.1 million and a GAAP net loss of $65.58 million. In comparison, last year the company earned a revenue of $10.29 million and had a GAAP net loss of $48.56 million
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KYMR in relation to earlier this year. Most recently, in March 2025, Jeremy Chadwick, the COO of KYMR sold 1,383.00 shares for a total of $42,103.92.
